Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Seok Mo Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Cancer Res Treat. 2018;50(1):195-203.   Published online March 21, 2017
DOI: https://doi.org/10.4143/crt.2016.376
AbstractAbstract PDFPubReaderePub
Purpose
Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of paclitaxel. Here,we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment.
Materials and Methods
In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3weeks (6 cycles). The primary endpointwas the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR).
Results
Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ≥ grade 3 occurred in one patient receiving Genexol. All toxicities were manageable.
Conclusion
Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

Citations

Citations to this article as recorded by  
  • Medical nanoscale materials for virus-induced cervical cancer therapeutic modalities: For targeting delivery
    Adane Adugna, Mamaru Getinet, Gashaw Azanaw Amare, Mohammed Jemal
    OpenNano.2025; 21: 100221.     CrossRef
  • From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment
    Fatemah Basingab, Omniah Alshahrani, Ibtehal Alansari, Nada Almarghalani, Nada Alshelali, Abeer Alsaiary, Najwa Alharbi, Kawther Zaher
    Breast Cancer: Targets and Therapy.2025; Volume 17: 27.     CrossRef
  • PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model
    Wendy K. Nevala, Liyi Geng, Hui Xie, Noah A. Stueven, Svetomir N. Markovic
    International Journal of Molecular Sciences.2025; 26(7): 3295.     CrossRef
  • Nano-drug delivery systems based on biodegradable polymers for the therapy of gynecological malignancies
    Keer Jin, Hanxue Zhang, Yuwei Yang, Yan Gao
    International Journal of Polymeric Materials and Polymeric Biomaterials.2024; 73(14): 1262.     CrossRef
  • Dual stimuli-responsive polymeric prodrug consisting of reversible covalent bonded celastrol for tumor targeted delivery
    Jiangtao Su, Meng Rao, Heshuang Dai, Le Cai, Fan Ye, Lu Ye, Yuchen Hu, Ban Chen, Xiaoxia Guo
    Macromolecular Research.2024; 32(2): 173.     CrossRef
  • Designing nanodiscs as versatile platforms for on-demand therapy
    Qianwen Mu, Haolan Deng, Xiaoyu An, Gang Liu, Chao Liu
    Nanoscale.2024; 16(5): 2220.     CrossRef
  • Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
    Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
    Journal of Oncology Pharmacy Practice.2024; 30(2): 367.     CrossRef
  • Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond
    Yalan Zhu, Lingling Xu, Yong Kang, Qinzhen Cheng, Yiling He, Xiaoyuan Ji
    Biomaterials.2024; 306: 122478.     CrossRef
  • Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion
    Fei Li, Yahong Wang, Dandan Chen, Yunjie Du
    International Journal of Molecular Sciences.2024; 25(3): 1396.     CrossRef
  • Delivery of Nucleic Acid Drugs for Tumor Therapy: Opportunities and Challenges
    Dandan Sun, Wenjia Tan, Jianan Zhao, Yafei Tian, Siqi Li, Zhiqi Zhang, Xinzhe Dong, Xiaonan Liu, Na Liu, Ping Jiao, Jie Ma
    Fundamental Research.2024;[Epub]     CrossRef
  • Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of the ovary: a prospective cohort study with historical controls
    Soo Jin Park, Joo-Hyuk Son, Tae-Wook Kong, Suk-Joon Chang, Hee Seung Kim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Co-Assembly of Cancer Drugs with Cyclo-HH Peptides: Insights from Simulations and Experiments
    Anastasia Vlachou, Vijay Bhooshan Kumar, Om Shanker Tiwari, Sigal Rencus-Lazar, Yu Chen, Busra Ozguney, Ehud Gazit, Phanourios Tamamis
    ACS Applied Bio Materials.2024; 7(4): 2309.     CrossRef
  • Biomarkers in Ovarian Cancer: Towards Personalized Medicine
    Carlos López-Portugués, María Montes-Bayón, Paula Díez
    Proteomes.2024; 12(1): 8.     CrossRef
  • Internalization of transferrin-tagged Myxococcus xanthus encapsulins into mesenchymal stem cells
    Anna N. Gabashvili, Natalya A. Alexandrushkina, Elizaveta N. Mochalova, Daria V. Goliusova, Ekaterina N. Sapozhnikova, Pavel I. Makarevich, Petr I. Nikitin
    Experimental Biology and Medicine.2024;[Epub]     CrossRef
  • Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
    Ana Serras, Célia Faustino, Lídia Pinheiro
    Pharmaceutics.2024; 16(8): 1047.     CrossRef
  • Polyesters and Polyester Nano- and Microcarriers for Drug Delivery
    Stanislaw Slomkowski, Teresa Basinska, Mariusz Gadzinowski, Damian Mickiewicz
    Polymers.2024; 16(17): 2503.     CrossRef
  • Nanotheranostics for gynecological cancers: a path forward for Africa
    Mutia Kehwalla Aza, Anavami Suberu, Mahmood Balogun, Goodness Adegbola, Mohamed Alie Sankoh, Thomas Oyediran, Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Chinonyelum Emmanuel Agbo
    Medical Oncology.2024;[Epub]     CrossRef
  • Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics
    Mahua Sarkar, Yang Wang, Oscar Ekpenyong, Dong Liang, Huan Xie
    WIREs Nanomedicine and Nanobiotechnology.2023;[Epub]     CrossRef
  • Cancer treatment and toxicity outlook of nanoparticles
    Neetika, Mamta Sharma, Pankaj Thakur, Paras Gaur, Gokana Mohana Rani, Sarvesh Rustagi, Rishi Kumar Talreja, Vishal Chaudhary
    Environmental Research.2023; 237: 116870.     CrossRef
  • Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
    Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
    Nanomedicine.2023; 18(10): 833.     CrossRef
  • Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
    Tetiana Korzun, Abraham S. Moses, Parham Diba, Ariana L. Sattler, Brennan Olson, Olena R. Taratula, Tanja Pejovic, Daniel L. Marks, Oleh Taratula
    Small.2023;[Epub]     CrossRef
  • Nanoprobe-based molecular imaging for tumor stratification
    Xianbin Ma, Mingchuan Mao, Jiaqi He, Chao Liang, Hai-Yan Xie
    Chemical Society Reviews.2023; 52(18): 6447.     CrossRef
  • Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
    Bakr Ahmed, Anuradha Sharma, Zakiya Usmani, Garima Sharma, Joga Singh, Radhika Yadav, Indu Sharma, Indu Pal Kaur
    Journal of Drug Delivery Science and Technology.2023; 88: 104945.     CrossRef
  • Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
    So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim
    Cancer Research and Treatment.2023; 55(4): 1346.     CrossRef
  • Effective Cancer Management: Inimitable Role of Phytochemical Based Nano- Formulations
    Aman Upaganlawar, Satish Polshettiwar, Sushil Raut, Amol Tagalpallewar, Vishal Pande
    Current Drug Metabolism.2022; 23(11): 869.     CrossRef
  • Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
    Franck Marquet, Viorica Patrulea, Gerrit Borchard
    Polymer Journal.2022; 54(2): 199.     CrossRef
  • Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic
    Vladimir A. Ljubimov, Arshia Ramesh, Saya Davani, Moise Danielpour, Joshua J. Breunig, Keith L. Black
    Advanced Drug Delivery Reviews.2022; 181: 114033.     CrossRef
  • Nanocarriers targeting the diseases of the pancreas
    Nurbanu Demirtürk, Erem Bilensoy
    European Journal of Pharmaceutics and Biopharmaceutics.2022; 170: 10.     CrossRef
  • The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
    Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
    Seminars in Cancer Biology.2022; 86: 873.     CrossRef
  • Beyond separation: Membranes towards medicine
    Ying Xie, Zhenyu Chu, Wanqin Jin
    Journal of Membrane Science Letters.2022; 2(1): 100020.     CrossRef
  • Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy
    Sajad Fakhri, Seyed Zachariah Moradi, Akram Yarmohammadi, Fatemeh Narimani, Carly E. Wallace, Anupam Bishayee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements
    Atieh Jahangiri-Manesh, Marziyeh Mousazadeh, Shirinsadat Taji, Abbas Bahmani, Atefeh Zarepour, Ali Zarrabi, Esmaeel Sharifi, Mostafa Azimzadeh
    Pharmaceutics.2022; 14(3): 664.     CrossRef
  • Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
    Ekati Drakopoulou, Nicholas P. Anagnou, Kalliopi I. Pappa
    Cancers.2022; 14(13): 3238.     CrossRef
  • Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
    Suhaila O. Alhaj-Suliman, Emad I. Wafa, Aliasger K. Salem
    Advanced Drug Delivery Reviews.2022; 189: 114482.     CrossRef
  • Metabolic Signatures of Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles in Differentiated THP-1 Cells Derived with Liquid Chromatography-Mass Spectrometry-based Metabolomics
    Mohammad A. Al-natour, Salah Abdelrazig, Amir M. Ghaemmaghami, Cameron Alexander, Dong-Hyun Kim
    ACS Omega.2022; 7(33): 28806.     CrossRef
  • Pathogen-derived peptides in drug targeting and its therapeutic approach
    Seok-Jun Mun, Euni Cho, Jae-Sung Kim, Chul-Su Yang
    Journal of Controlled Release.2022; 350: 716.     CrossRef
  • Application of single and cooperative different delivery systems for the treatment of intervertebral disc degeneration
    Zongtai Liu, Changfeng Fu
    Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
  • Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions
    Koustav Pal, Rahul A. Sheth
    Cancers.2022; 15(1): 196.     CrossRef
  • Nanoparticle delivery systems to combat drug resistance in ovarian cancer
    Emily M. Miller, Timothy M. Samec, Angela A. Alexander-Bryant
    Nanomedicine: Nanotechnology, Biology and Medicine.2021; 31: 102309.     CrossRef
  • Engineering precision nanoparticles for drug delivery
    Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, Robert Langer
    Nature Reviews Drug Discovery.2021; 20(2): 101.     CrossRef
  • Clinical applications of nanomedicines in lung cancer treatment
    Mohammad Norouzi, Pierre Hardy
    Acta Biomaterialia.2021; 121: 134.     CrossRef
  • Lyophilization stabilizes clinical‐stage core‐crosslinked polymeric micelles to overcome cold chain supply challenges
    Tarun Ojha, Qizhi Hu, Claudio Colombo, Jan Wit, Michiel van Geijn, Mies J. van Steenbergen, Mahsa Bagheri, Hiltrud Königs‐Werner, Eva Miriam Buhl, Ruchi Bansal, Yang Shi, Wim E. Hennink, Gert Storm, Cristianne J. F. Rijcken, Twan Lammers
    Biotechnology Journal.2021;[Epub]     CrossRef
  • Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface
    Shannon R. Tracey, Peter Smyth, Caroline J. Barelle, Christopher J. Scott
    Biochemical Society Transactions.2021; 49(5): 2253.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Engineering Considerations to Produce Bioactive Compounds from Plant Cell Suspension Culture in Bioreactors
    Elizabeth Alejandra Motolinía-Alcántara, Carlos Omar Castillo-Araiza, Mario Rodríguez-Monroy, Angélica Román-Guerrero, Francisco Cruz-Sosa
    Plants.2021; 10(12): 2762.     CrossRef
  • Clinical applications of nanomedicine in cancer therapy
    Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
    Drug Discovery Today.2020; 25(1): 107.     CrossRef
  • Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products
    April L. Risinger, Lin Du
    Natural Product Reports.2020; 37(5): 634.     CrossRef
  • Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis


    Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
    International Journal of Nanomedicine.2020; Volume 15: 1731.     CrossRef
  • Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
    Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
    Advanced Drug Delivery Reviews.2020; 156: 80.     CrossRef
  • Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
    Yuan Li, Yan Gao, Xi Zhang, Hongyan Guo, Huile Gao
    International Journal of Pharmaceutics.2020; 591: 119986.     CrossRef
  • Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
    Kaiting Wu, Lin Yu, Jiandong Ding
    Journal of Chemical Education.2020; 97(11): 4158.     CrossRef
  • Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use


    Madhusmita Dhupal, Devasish Chowdhury
    International Journal of Nanomedicine.2020; Volume 15: 9125.     CrossRef
  • Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
    Yuxuan Dai, Xingguang Cai, Xinzhou Bi, Chunxia Liu, Na Yue, Ying Zhu, Jiaqi Zhou, Mian Fu, Wenlong Huang, Hai Qian
    European Journal of Medicinal Chemistry.2019; 171: 104.     CrossRef
  • A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
    The Oncologist.2019; 24(6): 751.     CrossRef
  • Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging
    Xiaoxue Xie, Yu Chen, Zhongyuan Chen, Yi Feng, Jing Wang, Tingting Li, Shun Li, Xiang Qin, Chunhui Wu, Chuan Zheng, Jie Zhu, Fengming You, Yiyao Liu, Hong Yang
    ACS Applied Materials & Interfaces.2019; 11(47): 43865.     CrossRef
  • Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
    A. G. Kedrova, S. E. Krasilnikov, D. A. Astakhov, V. V. Kosyy
    Tumors of female reproductive system.2019; 15(3): 37.     CrossRef
  • Improving Drug Delivery of Micellar Paclitaxel against Non‐Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator
    Ling Zhang, Zhengsheng Liu, Chao Kong, Chun Liu, Kuan Yang, Huijun Chen, Jinfeng Huang, Feng Qian
    Small.2018;[Epub]     CrossRef
  • 13,783 View
  • 362 Download
  • 60 Web of Science
  • 57 Crossref
Close layer
The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study
Kyeong A So, Mi Jung Kim, Ki-Heon Lee, In-Ho Lee, Mi Kyung Kim, Yoo Kyung Lee, Chang-Sun Hwang, Mi Seon Jeong, Mee-Kyung Kee, Chun Kang, Chi Heum Cho, Seok Mo Kim, Sung Ran Hong, Ki Tae Kim, Won-Chul Lee, Jong Sup Park, Tae Jin Kim
Cancer Res Treat. 2016;48(4):1313-1320.   Published online March 9, 2016
DOI: https://doi.org/10.4143/crt.2016.013
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the impact of high-risk human papillomaviruses (HPVs) other than HPV 16/18 on the natural course of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL).
Materials and Methods
The study population was derived from the Korean HPV cohort (2010-2014). Women aged 20 to 60 who satisfied the criteria of having both HPV infection and abnormal cervical cytology of either ASC-US or LSIL were recruited from five institutions nationwide. Enrolled patients underwent cervical cytology and HPV DNA testing every 6 months.
Results
A total of 1,158 patients were enrolled. The 10 most common HPV types were HPV 16 (12.3%), 58 (10.0%), 56 (8.8%), 53 (8.4%), 52 (7.7%), 39 (6.2%), 18 (6.0%), 51 (5.7%), 68 (5.1%), and 66 (4.6%). Among these patients, 636 women were positive for high-risk HPVs other than HPV 16 or 18, and 429 women were followed for more than 6 months. Cytology evaluations showed progression in 15.3% of women, no change in 22.6%, and regression in 62.1% of women at 12 months. In cases of HPV 58 single infection, a more highly significant progression rate, compared to other high-risk types, was observed at 6 months (relative risk [RR], 3.3; 95% confidence interval [CI], 2.04 to 5.30; p < 0.001) and 12 months (RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001).
Conclusion
HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. HPV 58 was the second most common type, with a high progression rate of cervical cytology.

Citations

Citations to this article as recorded by  
  • Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes
    Farah S. Baban, Michael R. Henry, Margaret E. Long, Meredith A. VandeHaar, Grant M. Spears, Sarah M. Jenkins, Diva R. Salomao
    Journal of Lower Genital Tract Disease.2024; 28(1): 43.     CrossRef
  • Cervical intraepithelial neoplasia in non-16/18 high-risk human papilloma virus positive/cytology negative women: An alternative approach in poor resource areas
    Fariba Yarandi, Elham Shirali, Elham Feizabad, Sara Ramhormoziyan, Soheila Sarmadi, Maryam SadrAmeli, Elham Arshadi
    Taiwanese Journal of Obstetrics and Gynecology.2023; 62(2): 299.     CrossRef
  • Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer
    Fatema Alzahraa Samy Amin, Zeba Un Naher, P. Shaik Syed Ali
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 8077.     CrossRef
  • Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
    Daniel Sausen, Oren Shechter, Elisa Gallo, Harel Dahari, Ronen Borenstein
    Cancers.2023; 15(14): 3692.     CrossRef
  • Association strength of E6 to E6AP/p53 complex correlates with HPV‐mediated oncogenesis risk
    Matheus Vitor Ferreira Ferraz, Isabelle Freire Tabosa Viana, Danilo Fernandes Coêlho, Carlos Henrique Bezerra da Cruz, Maíra de Arruda Lima, Madson Allan de Luna Aragão, Roberto Dias Lins
    Biopolymers.2022;[Epub]     CrossRef
  • Diagnostic performance of immediate colposcopy among women with high‐risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology
    Serdar Aydın, Hande Nur Öncü, Dilek Sema Arıcı
    Journal of Obstetrics and Gynaecology Research.2021; 47(2): 720.     CrossRef
  • Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer
    Rachelle P. Mendoza, Tahmineh Haidary, Elmer Gabutan, Ying Yin Zhou, Zaheer Bukhari, Courtney Connelly, Wen-Ching Lee, Yi-Chun Lee, Raj Wadgaonkar, Raag Agrawal, M. A. Haseeb, Raavi Gupta
    Scientific Reports.2021;[Epub]     CrossRef
  • Distribution of HPV genotypes among women with abnormal cytology results in Alberta, Canada
    Sabrina S Plitt, Ryan Kichuk, Sheena Geier, Trenton Smith, Felicia Roy, Alberto Severini, Carmen L Charlton
    Journal of the Association of Medical Microbiology and Infectious Disease Canada.2021; 6(2): 94.     CrossRef
  • The Clinical Significance and Utility of HPV-DNA Testing in Korean Women with Atypical Glandular Cells in Cervical Pap Tests: An Analysis of 311 Cases at a Single Institution
    Tae-Kyu Jang, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
    Cancer Investigation.2021; 39(10): 885.     CrossRef
  • Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study
    Jaehyun Seong, Sangmi Ryou, JeongGyu Lee, Myeongsu Yoo, Sooyoung Hur, Byeong-Sun Choi
    Virology Journal.2021;[Epub]     CrossRef
  • Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China
    Zhiling Wang, Ting Liu, Yunjian Wang, Ying Gu, Hui Wang, Jingkang Liu, Baoxia Cui, Xingsheng Yang
    Infectious Agents and Cancer.2020;[Epub]     CrossRef
  • Co-infection between genotypes of the human papillomavirus and Chlamydia trachomatis in Mexican women
    Marco A Escarcega-Tame, Marcela López-Hurtado, Marcos R Escobedo-Guerra, Elba Reyes-Maldonado, Graciela Castro-Escarpulli, Fernando M Guerra-Infante
    International Journal of STD & AIDS.2020; 31(13): 1255.     CrossRef
  • Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach
    Giorgio Bogani, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Umberto Leone Roberti Maggiore, Francesca Taverna, Claudia Lombardo, Chiara Borghi, Cono Scaffa, Domenica Lorusso, Francesco Raspagliesi
    European Journal of Cancer Prevention.2019; 28(2): 81.     CrossRef
  • Human papillomavirus genotype-specific risk in cervical carcinogenesis
    Kyeong A So, In Ho Lee, Ki Heon Lee, Sung Ran Hong, Young Jun Kim, Hyun Hee Seo, Tae Jin Kim
    Journal of Gynecologic Oncology.2019;[Epub]     CrossRef
  • Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women
    Eun Young Ki, Yoon Kyung Lee, Ahwon Lee, Jong Sup Park
    Yonsei Medical Journal.2018; 59(5): 662.     CrossRef
  • Genetic variability in E6, E7 and L1 genes of Human Papillomavirus 62 and its prevalence in Mexico
    Cristina Artaza-Irigaray, María Guadalupe Flores-Miramontes, Dominik Olszewski, María Teresa Magaña-Torres, María Guadalupe López-Cardona, Yelda Aurora Leal-Herrera, Patricia Piña-Sánchez, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy
    Infectious Agents and Cancer.2017;[Epub]     CrossRef
  • 33,962 View
  • 301 Download
  • 16 Web of Science
  • 16 Crossref
Close layer
Case Reports
Hepatocellular Carcinoma Presenting as Uterine Metastasis
Woo Dae Kang, Cheol Hong Kim, Moon Kyung Cho, Jong Woon Kim, Ji Shin Lee, Yoon Ha Kim, Ho Sun Choi, Seok Mo Kim
Cancer Res Treat. 2008;40(3):141-144.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.141
AbstractAbstract PDFPubReaderePub

Metastatic extragenital cancer that spreads to the uterus is rare. When it occurs, the extragenital primary disease is often in the breast or gastrointestinal tract. We report here on a case of hepatocellular carcinoma (HCC) that metastasis to the uterus. The patient was admitted for evaluation of a pelvic mass. The serum alpha-fetoprotein level was highly elevated. Magnetic resonance imaging of the abdomen and pelvis showed hepatic and uterine masses. The patient underwent surgical treatment. The histopathologic findings and immunohistochemical staining results of the uterine mass were char acteristics of metastatic HCC. The endometrium and both ovaries were free of tumor. Up to now, there have been only two cases of uterine metastasis from HCC reported in the English literature. This case is the first documented instance of a metastatic uterine tumor from HCC that spared both ovaries.

Citations

Citations to this article as recorded by  
  • Pelvis metastasis with rectal infiltration in hepatocellular carcinoma - a rare case report
    Arnetta Naomi Louise Lalisang, Davin Nathan Wijaya, Indah Jamtani, Vania Myralda Giamour Marbun, Yarman Mazni, Toar Jean Maurice Lalisang, Marini Stephanie, Taufik Agung Wibowo
    European Journal of Medical Case Reports.2024;[Epub]     CrossRef
  • Pelvis metastasis with rectal infiltration in hepatocellular carcinoma - a rare case report
    Arnetta Naomi Louise Lalisang, Davin Nathan Wijaya, Indah Jamtani, Vania Myralda Giamour Marbun, Yarman Mazni, Toar Jean Maurice Lalisang, Marini Stephanie, Taufik Agung Wibowo
    European Journal of Medical Case Reports.2024;[Epub]     CrossRef
  • Rare Site Hepatocellular Carcinoma Metastasis


    Enrique Boldo, Ana Santafe, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Pérez de Lucia, Nuria Bosch Aparicio
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 39.     CrossRef
  • Cholangiocarcinoma Presenting as Uterine Metastasis
    W. Dendas, L. Cappelle, J. Verguts, G. Orye
    Case Reports in Obstetrics and Gynecology.2014; 2014: 1.     CrossRef
  • Localized Uterine Recurrence of Hepatocellular Carcinoma 4 Years after Curative Resection
    Sang Jin Lee, Jung Woo Shin, Neung Hwa Park, Yang Won Nah, Hang Jo Yoo, Yoong Ki Jung, Hye Jeong Choi
    Korean Journal of Medicine.2012; 82(5): 603.     CrossRef
  • Endometrial Carcinomas
    Carla Bartosch, José Manuel Lopes, Esther Oliva
    Advances in Anatomic Pathology.2011; 18(6): 415.     CrossRef
  • 8,528 View
  • 67 Download
  • 6 Crossref
Close layer
Primary Epithelial Ovarian Carcinoma with Gastric Metastasis Mimic Gastrointestinal Stromal Tumor
Woo Dae Kang, Cheol Hong Kim, Moon Kyoung Cho, Jong Woon Kim, Ji Shin Lee, Seong Yeob Ryu, Yoon Ha Kim, Ho Sun Choi, Seok Mo Kim
Cancer Res Treat. 2008;40(2):93-96.   Published online June 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.2.93
AbstractAbstract PDFPubReaderePub

Epithelial ovarian carcinoma rarely metastasizes to the parenchyma of the stomach. A 55-years-old woman presented with epigastric pain and a feeling of fullness for one month. A subsequent contrast-enhanced CT scan demonstrated a 4.5×4 cm submucosal mass with focal ulceration in the gastric antrum, and this finding was suggestive of GIST. After gastric antrectomy, the final pathology showed metastatic gastric tumor from a primary ovarian serous carcinoma. Because epithelial ovarian carcinoma is usually spread along the peritoneal surface, stomach involvement is rare. Furthermore, transmural gastric metastasis is very rare in a patient with primary ovarian carcinoma. Until now, there has been no reported case of stomach involvement at presentation in a patient with primary ovarian carcinoma. We present here a case of ovarian carcinoma with gastric metastasis that mimicked GIST.

Citations

Citations to this article as recorded by  
  • Ovarian serous carcinoma with stomach metastasis: a rare case report and literature review
    Jia-Li Hu, Zhao-Jiao Guo, Chun Wang, Jun Yan, Hao Yang
    Journal of International Medical Research.2024;[Epub]     CrossRef
  • Gastrointestinal Stromal Tumors (GISTs) Mimicking Primary Ovarian Tumors or Metastasizing to the Ovaries: A Systematic Literature Review
    Gabriele Tonni, Andrea Palicelli, Maria Bassi, Federica Torricelli, Ilaria Vacca, Lorenzo Aguzzoli, Vincenzo Mandato
    Cancers.2024; 16(13): 2305.     CrossRef
  • Solitary Gastric Metastasis from a Stage IA Serous Ovarian Carcinoma: A Case Report with Literature Review
    Keishi Mizuguchi, Hiroshi Minato, Isao Yoshida, Junpei Iwadare, Kayo Kayahashi, Yuki Mitani, Kazuyoshi Watanabe
    Internal Medicine.2017; 56(8): 915.     CrossRef
  • Isolated gastric recurrence from ovarian carcinoma: A case report
    QIAN LIU, QIAN-QIAN YU, HAO WU, ZHI-HONG ZHANG, REN-HUA GUO
    Oncology Letters.2015; 9(3): 1173.     CrossRef
  • Improved Survival of a Patient with Gastric and Other Multiple Metastases from Ovarian Cancer by Multimodal Treatment: A Case Report
    Seonmi Hwangbo, Oh Kyoung Kwon, Ho Young Chung, Wansik Yu
    Journal of Gastric Cancer.2015; 15(3): 218.     CrossRef
  • Clinicopathological features and treatment outcomes of metastatic tumors in the stomach
    Tsutomu Namikawa, Kazuhiro Hanazaki
    Surgery Today.2014; 44(8): 1392.     CrossRef
  • Gastric Metastasis from Ovarian Cancer Presenting as a Submucosal Tumor: A Case Report
    Eun Young Kim, Cho Hyun Park, Eun Sun Jung, Kyo Young Song
    Journal of Gastric Cancer.2014; 14(2): 138.     CrossRef
  • Gastric perforation secondary to metastasis from ovarian cancer: Case report
    Firas Obeidat, Ayman Mismar, Maha Shomaf, Mohammad Yousef, Kamil Fram
    International Journal of Surgery Case Reports.2013; 4(6): 541.     CrossRef
  • Multiple Gastric Metastases from Ovarian Carcinoma Diagnosed by Endoscopic Ultrasound with Fine Needle Aspiration
    Mehmet Akce, Sharon Bihlmeyer, Andrew Catanzaro
    Case Reports in Gastrointestinal Medicine.2012; 2012: 1.     CrossRef
  • Gastric metastasis from ovarian carcinoma diagnosed by EUS-FNA biopsy and elastography
    Silvia Carrara, Claudio Doglioni, Paolo Giorgio Arcidiacono, Pier Alberto Testoni
    Gastrointestinal Endoscopy.2011; 74(1): 223.     CrossRef
  • 11,390 View
  • 69 Download
  • 10 Crossref
Close layer
Original Articles
Hydrogen Peroxide Producing Lactobacilli in Women with Cervical Neoplasia
Ho Sun Choi, Ki Min Kim, Chol Hong Kim, Seok Mo Kim, Jong Seok Oh
Cancer Res Treat. 2006;38(2):108-111.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.108
AbstractAbstract PDFPubReaderePub
Purpose

It is well known that human papillomavirus (HPV) is the main cause of cervical neoplasia, and hydrogen peroxide-producing lactobacilli are the most important microorganisms for maintaining the balance of the vaginal ecosystem. The purpose of our study was to investigate the relationship of hydrogen peroxide-producing lactobacilli, cervical neoplasia and high-risk HPV.

Materials and Methods

We enrolled 1138 women with abnormal cervical smears or cervicograms who were referred to the department of Obstetrics and Gynecology at Chonnam National University Medical School. In all of them, 1,138 vaginal swabs were collected for the qualitative assay of hydrogen peroxide producing lactobacilli and 150 cervical swabs were used for the HPV hybrid capture II test without regard to the subjects' pregnancy status. In the non-pregnant women, 880 cervical biopsies and/or loop electrosurgical excision procedures were performed for making the histological diagnosis.

Results

There was no significant difference not only between the distribution of H2O2 producing lactobacilli and the cervical histology, but also between the distribution of H2O2 producing lactobacilli and the positivity for high-risk HPV.

Conclusions

Both cervical neoplasia and high-risk HPV may not be influenced by the existence of hydrogen peroxide producing lactobacilli in the vagina.

Citations

Citations to this article as recorded by  
  • Unravelling the Biological Interplay Between Genital HPV Infection and Cervicovaginal Microbiota in Sub-Saharan Africa: Implications for Cervical (Pre)cancer Prevention
    Harris Onywera, Zizipho Z. A. Mbulawa, Adrian Brink, Anna-Lise Williamson, Lamech M. Mwapagha
    Venereology.2024; 3(4): 211.     CrossRef
  • Antimicrobial activity of Lactobacillus against microbial flora of cervicovaginal infections
    Subramanyam Dasari, Raju Naidu Devanaboyaina Shouri, Rajendra Wudayagiri, Lokanatha Valluru
    Asian Pacific Journal of Tropical Disease.2014; 4(1): 18.     CrossRef
  • PCR‐based identification of eight lactobacillus species and 18 hr‐HPV genotypes in fixed cervical samples of south african women at risk of HIV and BV
    Joke A.M. Dols, Gregor Reid, Remco Kort, Frank H.J. Schuren, Hugo Tempelman, Tj. Romke Bontekoe, Hans Korporaal, E.M. Van der Veer, Pieter W. Smit, Mathilde E. Boon
    Diagnostic Cytopathology.2012; 40(6): 472.     CrossRef
  • 9,436 View
  • 80 Download
  • 3 Crossref
Close layer
The Clinical Values of Metaplasia, p 53, c - erbB2 and CEA Expression in Gallbladder Carcinoma
Seok Mo Kim, Seong Hwan Kim, Jeong Hwan Chang, Sung chul Lim, Chae Hong Suh
J Korean Cancer Assoc. 1999;31(6):1261-1270.
AbstractAbstract PDF
PURPOSE
We evaluated the correlation between the carcinogenesis of gallbladder and the expression of lysozyme, p53, c-erbB2 and CEA in gallbladder lesions.
MATERIALS AND METHODS
Thirty cases of gallbladder lesions (containing 17 cases of GB carcinoma) were examined. We analyzed the clinicopathologic findings of the early (stage I & II) and advanced carcinoma (stage III, IV & V) and those of carcinoma with or without metaplasia in the tumor. We performed p53, c-erbB2 and CEA immunohistochemical staining and compared their findings with those of normal mucosa and preneoplastic lesions. We also performed lysozyme immunohistochemical staining and compared its finding with metaplastic and non-metaplastic lesions.
RESULTS
There are two distinct genetic pathways in gallbladder cacinogenesis and metaplastic carcinoma was more frequent than non-metaplastic carcinoma. Metaplasia of gallbladder did not reveal any difference of the clinicopathologic findings and depth of invasion (Nevin stage). Lysozyme expression was found in all metaplastic lesions but non-expression did not indicate non-metaplastic lesions. p53 mutations and c-erbB2 alterations may have a role in the carcinogenesis of gallbladder carcinomas, especially, in a late event, and in an early and late events, respectively. The correlation of p53 and c-erbB2 expressions was found but which did not indicate that the co-expression was needed in the carcinogenesis. CEA immunohistochemical staining may be helpful in the differential diagnosis of benign lesions and precancerous and cancerous lesions of the gallbladder.
CONCLUSION
These results suggest that p53 mutations and c-erbB2 alterations may have a role in the carcinogenesis of gallbladder carcinomas, especially, in a late event, and in an early and late events, respectively.
  • 2,447 View
  • 15 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP